A Randomized Double-Blind Parallel Study of Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Phase of Trial: Phase III
Latest Information Update: 11 Feb 2016
At a glance
- Drugs Rabeprazole (Primary) ; Ranitidine
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- Sponsors Eisai Inc; Eisai Medical Research
- 26 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Sep 2009 Eisai Inc added as trial sponsor and trial affiliate as reported by ClinicalTrials.gov.
- 28 Aug 2009 Planned end date changed from 1 Sep 2009 to 1 Nov 2009 as reported by ClinicalTrials.gov.